Glenmark to pay USD 7 mn to settle lawsuits with three entities in U.S.
1 month ago

Glenmark to pay USD 7 mn to settle lawsuits with three entities in U.S.

The Hindu  

Glenmark Pharmaceuticals on Monday said it will pay USD 7 million to three entities to settle lawsuits in the U.S. related to generic drugs. Glenmark said it along with subsidiary GlenmarkPharmaceuticals Inc, USA faced multiple antitrust and consumer protection lawsuits, including a class action, consolidated in the Eastern District of Virginia, U.S. in connection with generic Zetia, a drug for the treatment of cholesterol. The lawsuits alleged that in 2010, Glenmark entered an anticompetitive agreement to settle patent infringement litigation involving a patent related to ezetimibe with Schering Corporation and MSP Singapore Company LLC. In the antitrust and consumer protection litigation, the company was named as a defendant along with Schering Corporation, MSP Singapore Company LLC, Merck & Co, Inc, Merck Sharp & Dohme Corp, and Schering-Plough Corp. Glenmark and Merck disputed these claims and defended these matters vigorously.

Drug Lawsuits Usd Settle Glenmark Zetia  lawsuits  company  usd  glenmark  entities  mn  zetia  generic  related  pay  plaintiffs  merck  settle  settlement  drug

History of this topic

High Court bars Glenmark from making anti-diabetes drugs | IndiaTV News
10 years ago

High Court bars Glenmark from making anti-diabetes drugs | IndiaTV News

India TV News  

New Delhi: The Delhi High Court today restrained Indian firm Glenmark Pharmaceuticals from manufacturing, marketing or selling its anti-diabetes drugs Zita and Zita-Met, saying it has "prima facie" infringed the patent of US drug major Merck Sharp and Dohme. A bench of justices S Ravindra Bhat and Najmi Waziri, while granting the interim injunction, said MSD "has established a prima …

Glenmark’s generic anti-epilepsy drug in patent row
11 years, 8 months ago

Glenmark’s generic anti-epilepsy drug in patent row

The Hindu  

Glenmark Generics has confirmed that it filed Abbreviated New Drug Applications for Lacosamide tablets and oral solutions with the U.S. Food and Drug Administration with a paragraph IV certification for the Orange-book listed patent. A statement from Glenmark said that its ANDA products are generic versions of Vipmat, which are used in the treatment of partial-onset seizures in adults with …

Discover Related